SCHEMBL29498992

SCHEMBL29498992

CCCCC=CC(=O)N(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.47
CHRNB4 P30926 1/20 0.47
CHRNA3 P32297 1/20 0.47
CHRNA4 P43681 1/20 0.47
F7 P08709 1/20 0.44
F3 P13726 1/20 0.44
PPARG P37231 2/20 0.42
PPARA Q07869 2/20 0.42
ALDH1A1 P00352 1/20 0.41
PTPN1 P18031 1/20 0.40
GMNN O75496 1/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX15 P16050 1/20 0.39
APEX1 P27695 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23139471 1.00 CHRNB2 (0.47) CHRNB2CHRNB4CHRNA3CHRNA4F7
SCHEMBL16658741 0.92 PPARG (0.51) F7F3PPARGPPARAPTPN1
SCHEMBL16658746 0.92 PPARG (0.51) F7F3PPARGPPARAPTPN1
SCHEMBL16658747 0.92 PPARG (0.51) F7F3PPARGPPARAPTPN1
SCHEMBL8699813 0.92 PPARG (0.51) F7F3PPARGPPARAPTPN1
SCHEMBL8699814 0.92 PPARG (0.51) F7F3PPARGPPARAPTPN1
SCHEMBL16658744 0.92 PPARG (0.51) F7F3PPARGPPARAPTPN1
SCHEMBL16658740 0.92 PPARG (0.51) F7F3PPARGPPARAPTPN1
SCHEMBL16658743 0.92 PPARG (0.51) F7F3PPARGPPARAPTPN1
Hydrochloric Acid SCHEMBL29067637 0.92 PPARG (0.47) F7F3PPARGPPARAPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4599890-A2 SUNITINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2025-08-13 EP disclosed
US-20240358641-A1 PROCESSES FOR MAKING CYCLIC LIPID IMPLANTS FOR INTRAOCULAR USE ALLERGAN, INC. 2024-10-31 US disclosed
US-20240207287-A1 POLYMERIC IMPLANTS ALLERGAN INC (US) 2024-06-27 US disclosed
US-20240173236-A1 Topical Testosterone (T) for Promoting Hair Growth-Containing Formulations CORBOY JR EDWARD DUNNE (US) 2024-05-30 US disclosed
US-11833238-B2 Topical testosterone (T) for promoting hair growth-containing formulations CORBOY JR EDWARD DUNNE (US) 2023-12-05 US disclosed
US-20220087918-A1 Topical Testosterone (T) for Promoting Hair Growth-Containing Formulations CORBOY JR EDWARD DUNNE (US) 2022-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240207287-A1 POLYMERIC IMPLANTS PDE6C, PDE6A, PHOSPHO1 CHRNB2 1467/4885CHRNB4 1548/4885CHRNA3 1519/4885
US-20240358641-A1 PROCESSES FOR MAKING CYCLIC LIPID IMPLANTS FOR INTRAOCULAR USE LIPA, PDE6C, PDE6A CHRNB2 4131/4885CHRNB4 3858/4885CHRNA3 3891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.